Tidal Investments LLC Has $2.97 Million Holdings in Zoetis Inc. (NYSE:ZTS)

Tidal Investments LLC raised its position in Zoetis Inc. (NYSE:ZTS) by 3.4% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 15,210 shares of the company’s stock after purchasing an additional 500 shares during the period. Tidal Investments LLC’s holdings in Zoetis were worth $2,972,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Simplify Asset Management Inc. acquired a new position in Zoetis during the third quarter valued at approximately $11,684,000. B&L Asset Management LLC acquired a new stake in shares of Zoetis in the 3rd quarter valued at approximately $563,000. Dai ichi Life Insurance Company Ltd grew its stake in shares of Zoetis by 16.3% in the third quarter. Dai ichi Life Insurance Company Ltd now owns 74,499 shares of the company’s stock valued at $14,556,000 after buying an additional 10,427 shares in the last quarter. Assetmark Inc. raised its position in Zoetis by 17.9% during the third quarter. Assetmark Inc. now owns 120,303 shares of the company’s stock worth $23,505,000 after acquiring an additional 18,265 shares in the last quarter. Finally, Public Sector Pension Investment Board grew its stake in Zoetis by 947.3% in the 3rd quarter. Public Sector Pension Investment Board now owns 180,981 shares of the company’s stock valued at $35,360,000 after buying an additional 163,700 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors.

Zoetis Trading Down 0.4 %

Shares of ZTS stock opened at $178.18 on Monday. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $201.92. The stock’s fifty day moving average price is $180.58 and its two-hundred day moving average price is $181.32. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.27 and a current ratio of 3.69. The company has a market cap of $80.39 billion, a PE ratio of 33.49, a P/E/G ratio of 2.91 and a beta of 0.89.

Zoetis (NYSE:ZTS) last released its earnings results on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.46 by $0.12. The firm had revenue of $2.40 billion for the quarter, compared to analysts’ expectations of $2.29 billion. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The business’s revenue for the quarter was up 11.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.36 earnings per share. Equities analysts predict that Zoetis Inc. will post 5.9 EPS for the current fiscal year.

Zoetis Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, January 21st will be given a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a yield of 1.12%. This is a boost from Zoetis’s previous quarterly dividend of $0.43. The ex-dividend date of this dividend is Tuesday, January 21st. Zoetis’s dividend payout ratio is currently 32.52%.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on ZTS. Stifel Nicolaus boosted their price objective on Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a report on Wednesday, September 18th. Leerink Partnrs upgraded Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. Leerink Partners began coverage on shares of Zoetis in a research report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 target price for the company. UBS Group initiated coverage on shares of Zoetis in a research report on Monday, December 9th. They set a “neutral” rating and a $196.00 price target on the stock. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a report on Friday, October 11th. One equities research analyst has rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Zoetis presently has an average rating of “Buy” and a consensus price target of $216.70.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.